The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice.
Vanesa Ivetić
VI
Tkalcević
Berislav
B
Bosnjak
Ivanka
I
Pasalić
Boska
B
Hrvacić
Kristina
K
Situm
Miroslava Dominis
MD
Kramarić
Ines
I
Glojnarić
Vesna
V
Eraković Haber
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000378:metabolism; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D017291:Clarithromycin